Testing Menu
New discoveries are increasing the number of biomarker/drug associations at an unprecedented rate. It is more important than ever for cancer patients to have comprehensive molecular testing on their tumors.
Comprehensive Tumor Profiling
Caris molecular profiling utilizes a comprehensive approach to assess DNA, RNA and proteins to reveal a molecular blueprint to guide more precise and individualized treatment decisions from among 60+ FDA-approved therapies.
DNA
Whole Exome Sequencing
(Mutations, Indels & Copy Number Alterations)
RNA
Whole Transcriptome Sequencing
(Fusions & Variant Transcripts)
Protein
Immunohistochemistry
(Tumor-expressed antigens)
(Tumor-expressed antigens)
Technical Specifications
Sufficient tumor content (>20% tumor nuclei) must be present to complete all analysis. If you have questions, please contact Customer Support at (888) 979-8669.
FFPE/SLIDE TISSUE
Tumor content: >20% tumor nuclei
Paraffin Block (Preferred)
Formalin fixed tissue block (including core-needle biopsies, fine-needle aspirates or malignant fluid)
Unstained Slides
25 slides
FRESH TISSUE
10% neutral buffered formalin
Four to six (4-6) biopsies with 18 gauge needle preferred
Six to ten (6-10) biopsies with 22 needle accepted
MI Profile™ Specs
Approach
Multi-Omic Biomarker Analysis
Biological Coverage
DNA RNA Protein
Variant Coverage
Somatic
Technology
NGS (WES & WTS) IHC ISH PyroSeq
Genes | Depth/Read
22,000 | 500-1000x WES/60M WTS
Whole Exome Sequencing (WES) DNA
SNV INDEL CNA
Whole Transcriptome Sequencing (WTS) RNA
Fusion Variant Transcript
Genomic Signatures
MSI TMB LOH
Other
HLA Genotype*
Enrichment Method
Microdissection
Result Rate
>95%
Turnaround Time
10-14 Days
Specimen Quantity
20% Tumor (NGS) | 1 Slide per IHC/ISH
*Not available in New York state.
Biomarker Analysis by Tumor Type
The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.
Looking for a Specific Gene?
Use our full gene search to verify that it is included in Caris profiling, or browse the list of genes most commonly associated with cancer.
Search Genes >All Biomarker Analysis includes:
Whole Exome Sequencing (WES)
DNA
Genomic
Signatures
Signatures
Others
Point Mutations
Indels
Copy Number Alterations
HPV 16 and 18
MSI
TMB
LOH
HLA*
*Not available in New York state
Whole Transcriptome Sequencing (WTS)
RNA
Fusion Analysis
Variant Transcripts
Additional Testing:
Select tumor type to see specific tests to be performed.
Tumor Type:
No tumor selected
Additional Information:
- Caris applies the appropriate tumor-specific customizations standard with every order.
- In certain instances, some biomarkers or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
- For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibodies SP-142 and SP263 are used as appropriate.
- For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.